beyond spring pharma stock

By the close of. Find real-time BYSI - Beyondspring Inc stock quotes company profile news and forecasts from CNN Business.

Beyondspring Analyst Sees Little Trouble In Big China Nasdaq

According to the issued ratings of 6 analysts in the last year the consensus rating for BeyondSpring stock is Hold based on the current 1 sell rating 3 hold ratings and 2 buy ratings for BYSI.

. Wanchunbulin which owns a 100 interest in plinabulin. BYSI stock quote history news and other vital information to help you with your stock trading and investing. BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with the University of Washington in de novo drug discovery using a.

They recently received or are about to receive 30mn in upfront payment. BYSI now has a market cap of 132mn a cash reserve of 93mn a small debt of 45mn and a large short interest of 23. BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update.

View analysts price targets for BeyondSpring or view top-rated stocks among Wall Street analysts. The median estimate represents a 434 difference. In China we own a 5797 interest in our Chinese subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd.

Shares of BeyondSpring NASDAQ. The pharmaceutical company announced that its. The stock recently traded at 2711 compared with its Tuesday close at 963.

And China which ideally positions us to accomplish our near- and long-term objectives. In other cancer-drug news Infinity Pharmaceuticals. Clinical stage biopharma companies BeyondSpring BYSI and CTI BioPharma CTIC have gained 49 and 45 in the pre-market respectively on below-average volume as investors await.

Our lead asset a first-in-class agent plinabulin is a selective immunomodulating microtubule-binding agent that is being. The Company is focused on developing cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The 8 analysts offering price forecasts for BeyondSpring have a median target of 4075 with a high estimate of 10000 and a low estimate of 500.

20 2021 0222 PM. Is a clinical-stage global biopharmaceutical company. 1 We own global rights to plinabulin in all countries except China.

Find the latest BeyondSpring Inc. The service offers end-to-end research on both investing and trading ideas everyday and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked. Why Are BeyondSprings Shares Plunging Today.

Discover our most recent and upcoming events as well as download informative presentationsall right here. And Canada or 1-201-389-0879 International. They possess deep scientific clinical regulatory operational and financial expertise in both the US.

Events presentations. If youre experienced in therapeutics share our spirit for improving patients lives or are looking for an exciting opportunity with an innovative and solidly growing company wed like to meet you. Dr Dutta is.

BeyondSpring Pharmaceuticals Inc NASDAQBYSI shared the. - Company to host call today April 14 2022 at 800 am ET - Conference call can be accessed by dialing 877-451-6152 US. The live webcast can be accessed here or.

The Companyâs lead product Plinabulin which is being studied as an anti. Headquartered in New York City we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for millions of patients in need. It had slid 27 in the six months through Tuesday.

Shares of BeyondSpring BYSI -362 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. Learn more on. The average twelve-month price prediction for BeyondSpring is 3000 with a high price target of 6500 and a low price target of 500.

BYSI stock are taking off on Wednesday following an important update regarding the firms lung cancer treatment. This suggests a possible upside of 17634 from the stocks current price. The passcode is 13728822.

On average they expect BeyondSprings stock price to reach 3000 in the next twelve months. Their BYSI stock forecasts range from 500 to 6500. Our management team is made up of a strong and diverse group whose specialties range from early-phase development to global clinical development.

Circling Back On Beyondspring Bysi Stock Seeking Alpha

Cancer Biotech Beyondspring Hit By Weak Ipo

Beyondspring Bysi Stock Why The Price Substantially Fell Today

Beyondspring Bysi Market Capitalization

Beyondspring Stock Lack Of Transparency Creates Downside Risk Nasdaq Bysi Seeking Alpha

Beyondspring Pharmaceuticals Receives Complete Response Letter From The Fda For Plinabulin New Drug Application For Prevention Of Chemotherapy Induced Neutropenia Cin